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ABSTRACT 
Objective: The purpose of this study was to examine the prevalence of contraceptive use and the correlates of contraceptive use among females in 
Jeddah, Saudi Arabia. Moreover, it aimed to evaluate the knowledge about contraceptives and their use.  
Methods: The study was a community-based, cross-sectional descriptive survey conducted in Saudi Arabia from 28 September 2015 to 10 
December 2015. 
Results: The current study showed that the most commonly used contraceptives were intrauterine devices (IUD’s) (29.1%), followed by male 
condoms (27.7%). Most of the participants, 47.6%, started using a contraceptive after giving birth to their first child. Nearby, 60% of participants 
used contraceptives without a prescription or medical advice. Only 13.7 % of participants sought the advice of a pharmacist about which 
contraceptive they should use, while 30.6% and 24.2% of participants choose their contraceptive based on general knowledge and relatives’ 
experiences, respectively. Around 80% of participants stated that they did not have any problem while buying contraceptives from pharmacies 
without a prescription.  
Conclusion: Pharmacists and medical health providers need to fill this gap to improve the use of contraceptives. 
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INTRODUCTION 
Millions of women around the world have used contraceptives since 
their debut in 1957. Contraceptives remain the most prescribed 
medications for women ages 18-44 [1]. They enable women to 
control their reproduction and, thereby, other aspects of their lives, 
such as career and family [2]. 
Over the past 40 y, there have been significant advances in their 
development [3]. However, current policies and health care practices in 
some countries are based on scientific studies of contraceptive products 
that are no longer widely used [4]. Because country situations and 
program environments vary so greatly, it is inappropriate to set firm 
international guidelines on criteria for contraceptive use [5]. It is 
expected that national programs will use these recommendations for 
updating or developing their own contraceptive eligibility guidelines 
according to national health policies, needs, priorities and resources, 
while reflecting upon local values and preferences [6]. 
There are many contraceptive methods. Some of the most commonly 
used are: intrauterine devices (IUDs), long-acting and reversible 
contraceptive devices [7], an emergency contraceptive pill (ECP) 
taken orally after unprotected sex [8], and Levonorgestrel (LNG) 
also taken post-coitally "after intercourse", a method of emergency 
contraception (EC) that arrests or delays ovulation [9-11], and, the 
vaginal ring, which administers the delivery of selective 
progesterone receptor modulators (SPRMs) into the body [12]. 
Besides the methods listed above, a less complex method is the 
condom. Scientifically recommended as potential products for 
preventing infections attributable to human immunodeficiency 
viruses (HIV), condoms act as a barrier to keep sperm from entering 
the uterus [13]. Another wearable contraceptive choice is the patch 
which provides the systemic delivery of steroid hormones by 
transdermal technology using patches that contain estrogen or 
estrogen plus a progestin that has been successfully used for 
contraception [14]. Yet another product of choice, but more invasive, 
is the Implantable birth control rod, a matchstick-sized, flexible 
plastic, the surgically inserted device that releases progestin [15]. 
Female patients requiring treatment for pulmonary arterial 
hypertension (PAH) are advised to avoid pregnancy because of the 
high associated mortality rate [16], and oral contraception is one of 
the main methods of preventing pregnancy. They may be combined, 
or progesterone alone, the combined oral contraceptive pills (COCs) 
contain different combinations of the synthetic estrogens and are 
given to interfere with ovulation. In contrast, Progestin-only pills 
(POPs) may interfere with ovulation or with sperm function by 
thickening cervical mucus, making it difficult for sperm to move [17]. 
In most countries, various types of pills are available, and studies 
have shown an increased risk of venous thromboembolism with the 
use of combined oral contraceptives [18-20]. This risk differs 
according to a type of progestogen and decreases with both duration 
of use and decreasing estrogen dose [21, 22]. 
A progestogen-only injectable contraceptive is also available that 
acts for a long time and involves an injection of a progestin as a 
depot. Progestogen-only injectable contraception is highly effective, 
reversible and safe for most women [23].  
A less scientific alternative is the natural method. This involves 
recording the fertile and infertile times of a woman’s cycle to plan 
when to avoid pregnancy [24]. 
Using contraceptives in recent years, an integral part of a healthy 
lifestyle remains one of the most significant challenges for human 
beings; this challenge is the need to expand the use of contraceptives 
in Saudi Arabia and the world in controlled ways and to seek to 
address the effects of overpopulation. The who forecasts that the 
world's population, at present, which is about six billion people and 
is estimated to rise until it reaches almost eight billion by 2025, 
more than nine billion in 2050 [25]. 
The present study aims to determine the extent of use of 
contraceptives between people in Saudi Arabia. Moreover, its aim is 
to evaluate the knowledge about contraceptives and their use among 
the population as well as the intervention and effective 
communication between pharmacists and patients. 
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MATERIALS AND METHODS 
Methods 
The study was a community-based, cross-sectional survey 
conducted in Jeddah, Saudi from 28 September 2015 to 10 
December 2015. The current study was carried out on 618 adult 
participants ages 13-50 y for an assumed prevalence of 
contraceptives. Each participant was asked through direct 
contact to complete a structured self-administered 
questionnaire, available in Arabic and English. Pilot 
questionnaires were distributed for validation. Population 
samples were selected randomly through the distribution of the 
questionnaires through four high schools, one university, 
hospitals and an electronic survey. The collected data were 
pooled and analyzed by description. 
A structured questionnaire (table 1) consisted of three sections (i) 
the socioeconomic and demographic characteristics of the 
participant; (ii) participants' knowledge and attitudes regarding 
contraceptives use; and (iii) the intervention and effective 
communication between physician, pharmacist and patients. 
  
Table 1: Survey questionnaire 
Section (I) 
How old are you? 
What is your nationality? 
What is your level of education? 
What is your occupation? 
What is your income? 
Are you a smoker? 
What is your skin color?  
What is your husband's educational level? 
What is your husband's occupation? 
Section (II) 
Do you have general information about the menstrual cycle and what the best time would be for intercourse in order to conceive or avoid 
pregnancy? 
Do you have any general information about the different ways to prevent pregnancy or do you just know one thing? 
What do you think about contraception, in general? 
If you answered that it is not good, what is the reason? 
Do you or have you used contraceptives before? 
If you answered "yes", what are the types? 
At what age did you start to use contraceptives? 
Do you use contraceptives after having a child? 
What is the reason for contraceptive use? 
Do you have any chronic diseases? 
If you answered “yes”, which? 
Do you take any other drugs with contraceptives? 
If you answered “yes”, what are these drugs? 
Are you fully aware of the side effects of contraceptives?  
During your use of contraceptives, did any side effects appear? 
If you answered “yes”, what were they? 
Did any psychological changes occur while using contraceptives?  
Did you stop using immediately if you saw one of the following symptoms? 
- Headaches accompanied by nausea, vomiting and blurred vision  
- Obesity 
- Continuously feeling nervous 
Did the side effects persist after you stopped contraceptives?  
If you answered “yes”, did you consult a doctor? 
Did the pharmacist refuse to allow you to buy contraceptive pills without a prescription? 
Did you get pregnant while you were on a contraceptive? 
Did you try to change the type? 
If you answered “yes”, what is the reason?  
What is the appropriate time to use contraception? 
Section (III) 
Did you consult a physician before using a contraceptive? 
If you have not consulted a doctor, what was your source and choice of contraceptive?  
Did your doctor ask you to do some tests? 
If you answered “yes”, which one(s)? 
Did your doctor ask if you suffer from depression or psychological issues? 
Did you tell your doctor if you use some form of contraceptive? 
 
RESULTS 
A questionnaire was distributed in the Jeddah community, 618 
women were included in the study. The current study showed that 
the most commonly used contraceptive is an IUD, and intrauterine 
device (fig. 1). 
We found that 47.6% of participants started to use contraceptives 
after giving birth to their first child, and 64.8% decided to use them 
due to family planning (fig. 2). Furthermore, around 60% of the 
participants were using contraceptives without prescriptions. Their 
source for information about contraceptives was obtained mainly 
from general information (30.6%), and 24.2% of participants used 
relatives for advice on how to use contraceptives (fig. 3). Socio-
demographics of participants and its relation to the type of 
contraceptive use is shown in table 2. Furthermore, knowledge and 
attitude about contraceptives are stated in table 3. The role of 
physicians and pharmacists were obtained from participants’ 
responses, as presented in table 4. 
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Fig. 1: Prevalence of contraceptive use 
 
 
Fig. 2: Timing and source of contraceptive use 
 
 
Fig. 3: Prescribed contraceptives and source of information 
 
Table 2: Socio-demographics of participants and its relation to the type of contraceptive use 
Type of contraceptives number (%) 
 Male 
condom 
Tablets  Implant Patch  Natural  IUD Female 
condom  
Injection  Ring  




































































































































































































































































































































































Table 3: Knowledge and attitude about contraceptives 
Knowledge Response, number (%) 
Consult a physician before using  
 
 Yes 447 (72.21%) 
 No 128 (20.68%) 
Knowing about side effects 
 
 Yes 328 (52.99%) 
 No 20 (3.23%) 
 Not well 242 (39.10%) 
Knowing about contraceptive types 
 
 Tablets and pills 437 (70.60%) 
 Intrauterine device 70 (11.31%) 
 Hormone patch 16 (2.58%)  
 Vaginal ring 4 (0.65%) 
 Cultivation under the skin 1 (0.16%) 
 Female medical condoms 1 (0.16%) 
 Injection 3 (0.48%) 
 Others 19 (3.07%) 
Getting pregnant while using 
 
 Yes 86 (13.89%) 
 No 467 (75.44%) 
trying to change the type  
 
 Yes 301(48.63%) 
 No 244 (39.42%) 
If you answered “yes”, what is the reason (for changing) 
 
 Got pregnant 58 (9.37%) 
 Nausea 41 (6.62%) 
 Discomfort 167 (26.98%) 
 Fatty bags 12 (1.94%) 
 Other 98 (15.83%) 
  
Table 4: Role of physicians and pharmacists 
Role Response, number (%) 
Doctor asked to do some investigations  
 
 Yes 198(31.99%) 
 No 320(51.70%) 
The type of investigations  Fat level 30 (4.85%) 
 Liver function 8 (1.29%) 
 Blood sugar 13 (2.10%) 
 Pregnancy tests 73 (11.79%) 
 I do not know 49 (7.92%) 
Doctor asked about depression or psychological issues 
 
 Yes 82(13.25%) 
 No 429(69.31%)) 
Finding refusal from the pharmacist (being denied) while buying without a 
prescription 
 Yes 15 (2.42%) 
 No 491 (79.32%) 
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Since contraceptives first became available in the 1960s, they have 
been in extensive use throughout the world. Convenient and useful, 
birth control pills are also beneficial in treating menstrual disorders 
[26]. Effective contraception is a significant factor in a woman’s 
ability to plan her pregnancies, that is to achieve desired birth 
spacing and family size [27], changes in contraceptive method choice 
and use have not decreased the overall proportion of pregnancies 
that are unintended due to compositional changes in race, marital 
state, age, place of residence, education and income [28]. 
Most women in the US used pills (51%), with approximately 50% of 
users in the age range of 15–19, 40% being 20–24 y of age, and 10% 
at age 40–44 y [29]. There were changes in current method choice 
by race and education; pill use decreased among Black women to 
18%, but still higher than for White women. Three times as many 
women with a bachelor’s degree or higher relied on the pill (35%) 
[30]. And, 77.4% of women with public insurance, incomes above 
5,500$/month and who lived in nonmetropolitan areas were much 
more likely to use the pill as a contraceptive method compared with 
22.6% without insurance; and, those living in central cities were 
more likely to rely on the condom [31] 
Oral contraceptives (OCs) have been available in Canada for over 50 y 
until now, with decreasing estrogen doses, new progestins, and different 
dosing regimens. However, pill use in Canada is a second choice (36%) 
[32]. Among oral contraceptive users (36%) reported smoking either 
daily or occasionally. Almost all (99%) OC users took combined 
formulations containing ethinyl estradiol (EE) and progestin. Others took 
formulations containing 30 or more mcg of EE [33]. 
OC use decreased with age, 60.4% of women aged 15-30 reported taking 
OCs, 36.6% women aged 31-49 [34]. Oral contraceptives use was 
significantly higher for women with post-secondary education (44%) 
than for those for women who did not have this level of schooling, and, 
finally, among those who reported having prescription drug insurance 
coverage (57.2%) more than women who had no such benefits [35]. The 
percentage of White women using oral contraceptives was markedly 
lower (19%) compared with Black women who said they were not on 
the pill (30%) [36]. The World Health Organization (WHO) considers the 
prevalence of contraceptive usage among Saudi society in Riyadh city as 
one of the determinants of women’s health and empowerment in that 
society. Some societies use contraceptives to regulate pregnancies and in 
birth spacing. Religious issues may also play a significant role in 
determining how couples view such issues as contraception. Certain 
religions do not permit the use of contraception, and children from 
religious families may not even know the essentials on birth control 
methods [22]. The current study shows that the preferable type of 
contraception in Riyadh is the pill (71.7%). Use of different types of 
contraception according to age in the current study revealed that young 
females preferred the use of the vaginal ring and older females preferred 
either the IUD or pills; 21.1% aged 17-25 y old; 40.9% of pill users aged 
26-35 y old; and 33% aged 36-50 y [37]. 
Education on various methods of birth control, as well as the 
distribution of contraceptives, is a significant concern for the 
international community, women who have a bachelor’s degree or 
higher are 78.1% [38]. The current study illustrates that the attitude 
of females towards contraception was affected by their working 
status, finding it was better among housewives, more than half were 
working (52.1%); and only 3.9% of participants had an income of 
less than 3,000 riyals/month, while 44.1% had an income higher 
than 13,000 riyals/month. The majority of the sample was married 
(94.4%) [39]. Only 4.3% of Saudi Arabian women used pills as a 
contraceptive method because they think the other methods provide 
more control than pills. Saudi women have purchased over six 
million birth control pills costing SR 108 million in 2014. Women 
usually buy certain brands, with the Gynera brand being in the lead 
with sales of SR 34.2 million, followed by Yasmin at SR 27.2 million, 
Marvelon at SR 23 million, and Neo Sampoon at SR 4,600,000 as 
reported the same year [40]. 
Preferences for fertility control include family size, the timing of 
establishing a family, and choice of occupation. Canadians and their 
health care providers are thus involved in infertility-related 
decisions that will fundamentally influence individual lives and 
society as a whole well into the future [41]. Family planning 
decisions affect and are influenced by emotional health, sexual 
attitudes and behaviors, gender equity, the quality of relationships, 
and respect between men and women [42]. Condom use was higher 
among all age-groups (99%) with the exception of men aged 45-49. 
Condom use was more common among males than females [43]. 
Condom use among White men was 60% but still higher in Black 
men. Non-educated men were slightly higher by 55.5% than those 
who are educated at 44.5% [44]. The statistics showed Americans 
using condoms as a second choice (30%); overall, 46% of men aged 
15–44 used condoms, and 54% were not. The percentage using, and 
the type of method used vary significantly by age [45]. A more 
significant percentage of White men (66%) were using condoms 
compared with Black men at 54% [46]. Research showed that many 
people in Riyadh continue to have fears and misconceptions about 
modern contraceptives. Condom use in Riyadh is low (1%) [47]. 
Approximately 27.7% of the Saudi Arabian population used [male] 
condoms, almost all condom users were employed (87.5%) and 
those above 40 y of age (51%) higher than for younger individuals. 
An Intrauterine contraceptive device (IUD) is a T-shaped device 
containing a copper thread or cylinders which is placed in the uterus 
by a health care provider. The IUD releases copper ions which 
immobilize the sperm and make inhibit their ability to move around 
in the womb but do not stop the ovaries from producing an egg each 
month [48]. 
An IUD is one of the contraceptive methods commonly used in the 
USA. The US rate remains significantly higher (9%) [49] than that in 
Canada (4.8%) and European countries. Use of an intrauterine 
contraceptive device (IUD) is associated with marked reductions in 
unintended pregnancy among adolescents [50]. In Riyadh, the IUD is 
a second choice (20.1%), according to age, young females preferred 
the use of vaginal rings and older females preferred either the IUD or 
pills. The percentage of highly educated women was higher (66.2%). 
The average income of IUD users was more than 13,000 
riyals/month [51]. In this research study, we found that the 
preferred method in Saudi Arabia was the IUD (29.1%); most having 
an average income of more than 10,000 riyals/month (75.5%). 
Younger women from19-30 were less likely to use IUD’s, but others 
ages 31-40 used them more (57.1%) and ages 40-above (24.4%). 
Most women the IUD having a bachelor’s degree (51%) and 
employed (53%). Also, Blacks at (69.3%) which is much more than 
Whites [52]. 
The contraceptive injection is a shot of hormones either in the 
muscle or under the skin that lasts for one up to 3 mo. It contains 
hormones, either a progestin alone or progestin and estrogen 
together that prevents the body from releasing eggs and thickens the 
mucus at the cervix. The way it works is similar to the pill or the 
ring, except the user does not have to remember to take it every day 
or week [53]. Women residing in the US are less likely to use the 
injection (3.1%) [54] then (1.7%) for Canadians and women in 
Riyadh (0.4%) [55], respectively. Contraceptive injection is probably 
not the best choice for those afraid of needles, so many countries do 
not utilize this method [56]. In Saudi Arabia, 7% of women used 
injectable contraceptives, and of this number, 87.5% were employed 
and not smokers. 
The types of contraceptive devices and methods have increased with 
the development of the transdermal patch. The efficacy and safety of 
this method is similar to those of combined oral contraceptives. 
However, it differs from the pill in the route of hormone delivery and 
frequency of administration [57]. The contraceptive patch is just as 
it states, it is a patch that resembles polished plaster and sticks to 
the skin. The patch is highly effective in preventing unwanted 
pregnancies by releasing hormones. The hormones, estrogen and 
progestin, are released continuously, entering the bloodstream 
through the skin [57]. Approximately 2.7% of US women had used 
the transdermal patch. Physicians did not consider combined 
hormonal contraceptives to be a suitable method for participating 
women, mainly due to the presence of contraindications or medical 
conditions [58]. Also, having a low usage rate is Riyadh at (2.4%) 
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[59] and then in Canada at 1.2% [60]. In Saudi Arabia, the 
contraceptive patch is negligible (0.1%) because Saudi women 
depend on other methods and some (12.5%) have a chronic disease, 
thus, prohibiting their ability to utilize this contraceptive. 
Another device, the implant contraceptive, is placed just below the 
skin of the upper arm, where it continually releases the hormone 
progestin in small doses from a reservoir into the bloodstream. The 
modern contraceptive prevalence rate remains low. It may initially 
cause a change in bleeding patterns and may cause weight gain, 
breast and abdominal pain [61]. Yet, the uptake of implants 
increased slightly from 2.1%% to 2.5% in the US, at the time of this 
study [62]. It is, however, still low in Canada (1.5%) [63] and in 
Riyadh (1.4%) [64]. In Saudi Arabia, the number of people using an 
implant contraceptive is 8.2%, their source of method choice based 
on general information and personal reading.  
Similar to the implant, a contraceptive ring is available that also 
eliminates the need for daily dosing. The contraceptive ring, also 
known as the vaginal ring, is a bright and flexible ring of 
polyethylene vinyl acetate that, once inserted into the vagina, slowly 
releases the hormones progestin and estrogen into the body to stop 
the ovaries from releasing eggs [39]. 
It may cause vaginal discharge, discomfort and irritation in the 
vagina, and weight gain. Because of these problems, the vaginal ring 
has the lowest rate of use by women in the United States (1.1%) 
[65], Canada (0.6%) [66] and Riyadh (1.2%) [67]. Vaginal ring usage 
is shallow among Saudi Arabian women (12%) but almost (99.6%) 
all having a higher income (more than 10,000 riyals/month). 
Contraceptive use and method choice may change over time for 
various reasons, including the availability of new methods and more 
considerable societal changes in fertility patterns. For example, the 
average age at first birth for women in the United States has 
increased in recent decades, at least partially because of an increase 
in first births to women aged 35 [68]. This suggests potential 
changes over time in the use of contraception by age as first births 
are delayed. Acceptance of and ability to correctly and consistently 
use this technology may create challenges for future ring-based 
microbe-cide trials in settings where this technology has not been 
introduced [69]. Natural Family Planning (NFP) is the ability of 
individuals and couples to anticipate and attain their desired 
number of children and the spacing and timing of their births [47]. 
Only 0.6% of women had never previously used contraceptive 
methods in the US [70]. If compared with Canadian women, only 
0.2% were in natural family planning [71]. 1.8% of women in Riyadh 
did not use contraception medications reported due to medical 
reasons; so, they depend on natural family planning. Women need 
methods that provide them with greater control; so, natural family 
planning is typically reflected by Saudi women (0.9%) [47]. This 
study has potential limitations includes inadequate sample size 
compared to population and lack of enough previous studies in the 
same geographical region.  
CONCLUSION  
Pharmacists and medical health providers have to fill the gap to 
improve the use of contraceptives. Government, policymakers, 
decision-makers and other stakeholders should intensify education 
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